Treatment algorithm in different “highest-risk” scenarios of CLL. Patients with 17p deletion or TP53 mutation, refractory CLL (refractory to fludarabine, fludarabine combination, and similar regimens) as well as patients with short PFS after FCR (or similar regimens, PCR, BR) have a very high risk of death within 2 years from treatment indication.^14,15,17  *The recommendations are not based on comparative trial data.